Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,448
  • Shares Outstanding, K 99,489
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,770 K
  • EBIT $ -29 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.38

Options Overview Details

View History
  • Implied Volatility 416.49% (+79.39%)
  • Historical Volatility 63.50%
  • IV Percentile 70%
  • IV Rank 25.74%
  • IV High 1,206.81% on 01/15/25
  • IV Low 142.50% on 09/22/25
  • Expected Move (DTE 8) 0.0340 (3.13%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 72
  • Volume Avg (30-Day) 421
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 20,707
  • Open Int (30-Day) 19,763
  • Expected Range 1.0526 to 1.1206

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8800 +22.73%
on 12/01/25
1.1200 -3.57%
on 12/10/25
+0.0400 (+3.85%)
since 11/11/25
3-Month
0.8800 +22.73%
on 12/01/25
1.3800 -21.74%
on 10/22/25
+0.0100 (+0.93%)
since 09/11/25
52-Week
0.7709 +40.10%
on 04/07/25
1.5900 -32.08%
on 07/28/25
-0.3500 (-24.48%)
since 12/11/24

Most Recent Stories

More News
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRxâ„¢ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
5 Under-the-Radar Biotech Stocks That Could Soar in 2026

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

SLN : 6.48 (+3.51%)
CRDL : 1.0850 (+0.46%)
TERN : 46.85 (+5.02%)
INO : 2.16 (-0.46%)
TARA : 5.80 (+1.05%)
ATRA : 17.59 (+4.49%)
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRxâ„¢ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRxâ„¢ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

(August 6, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRxâ„¢ over placebo.Reduction in ECV was associated with improvements...

CRDL.TO : 1.48 (unch)
CRDL : 1.0850 (+0.46%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.1933
2nd Resistance Point 1.1567
1st Resistance Point 1.1183
Last Price 1.0850
1st Support Level 1.0433
2nd Support Level 1.0067
3rd Support Level 0.9683

See More

52-Week High 1.5900
Fibonacci 61.8% 1.2771
Fibonacci 50% 1.1804
Last Price 1.0850
Fibonacci 38.2% 1.0838
52-Week Low 0.7709

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar